Brimonidine-LAPONITE® intravitreal formulation has an ocular hypotensive and neuroprotective effect throughout 6 months of follow-up in a glaucoma animal model

M.J. Rodrigo, MJ Cardiel, JM Fraile, S Mendez-Martinez, T Martinez-Rincon, M Subias, V. Polo, Jesus Ruberte Paris, T. Ramírez, E Vispe, C. Luna, J.A. Mayoral, Elena García-Martin*

*Corresponding author for this work

Research output: Contribution to journalArticleResearchpeer-review

Original languageEnglish
Pages (from-to)21;8(22):6246-6260. doi: 10.1039/d0bm01013h
JournalBiomaterials Science
Issue number8(22)
Publication statusPublished - Nov 2020

Cite this